Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Jun;65(6):2299–2305. doi: 10.1128/iai.65.6.2299-2305.1997

The decrease in nonsplenic interleukin-6 (IL-6) production after splenectomy indicates the existence of a positive feedback loop of IL-6 production during endotoxemia in dogs.

H S Moeniralam 1, W A Bemelman 1, E Endert 1, R Koopmans 1, H P Sauerwein 1, J A Romijn 1
PMCID: PMC175319  PMID: 9169767

Abstract

The spleen is involved in endotoxin-induced interleukin-6 (IL-6) production. To quantitate the relative contribution of the spleen to endotoxin-induced IL-6 production, we studied the effect of endotoxin (1.0 microg/kg of body weight) in control dogs (n = 7) and splenectomized dogs (n = 7). Blood for analysis of tumor necrosis factor (TNF) and IL-6 was sampled from the femoral artery and the portal, hepatic, and splenic (only in controls) veins. Arterial plasma endotoxin and cortisol levels were also measured. Whole-body IL-6 production was calculated by a deconvolution technique. Splenic IL-6 production in control dogs was measured from splenic blood flow and arteriovenous concentration differences. Endotoxin levels were higher in splenectomized dogs (P < 0.05) because of a decreased distribution volume (P < 0.05) and decreased clearance of endotoxin (P < 0.05). Endotoxin-induced plasma IL-6 levels were decreased by approximately 75% in splenectomized dogs (P < 0.01), and whole-body IL-6 production rates were severalfold lower (median of 8.7 mg/4 h and range of 3.9 to 11.4 mg/4 h versus a median of 32.3 mg/4 h and a range of 22.7 to 70.2 mg/4 h) (P < 0.05). However, in control dogs splenic IL-6 production (0.6 +/- 0.2 mg/4 h) was only approximately 2% of whole-body IL-6 production. Plasma TNF levels increased in both groups (P < 0.01) but were not different between the groups. Plasma cortisol levels were slightly higher in splenectomized dogs than in control dogs (P < 0.05). In conclusion, splenectomy decreases the distribution volume and clearance rate of endotoxin. Splenectomy results in decreased endotoxin-induced IL-6 production, which is caused not by the absence of splenic IL-6 production, but by a decrease in nonsplenic IL-6 production. Therefore, the spleen is an important mediator in the complete activation of nonsplenic IL-6 production by endotoxin.

Full Text

The Full Text of this article is available as a PDF (199.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Le J. M., Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 1989 Dec 1;143(11):3517–3523. [PubMed] [Google Scholar]
  2. Ali J., Duke K. Pneumatic antishock garment decreases hemorrhage and mortality from splenic injury. Can J Surg. 1991 Oct;34(5):496–501. [PubMed] [Google Scholar]
  3. Bottoms G. D., Gimarc S., Pfeifer C. Plasma concentrations of endotoxin following jugular or portal injections of endotoxin and following gastrointestinal ischemia due to hemorrhage. Circ Shock. 1991 Jan;33(1):1–6. [PubMed] [Google Scholar]
  4. Breuninger L., Goonewardene I. M., Dempsey W. L., Murasko D. M. Monocyte culture and adherence modifies LPS-induced IL-6 production and inhibition by hydrocortisone. Clin Immunol Immunopathol. 1994 Aug;72(2):264–272. doi: 10.1006/clin.1994.1140. [DOI] [PubMed] [Google Scholar]
  5. Brouckaert P., Spriggs D. R., Demetri G., Kufe D. W., Fiers W. Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med. 1989 Jun 1;169(6):2257–2262. doi: 10.1084/jem.169.6.2257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ertel W., Morrison M. H., Wang P., Ba Z. F., Ayala A., Chaudry I. H. The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins. Ann Surg. 1991 Aug;214(2):141–148. doi: 10.1097/00000658-199108000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  8. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., Faggioni R., Fantuzzi G., Ghezzi P., Poli V. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med. 1994 Oct 1;180(4):1243–1250. doi: 10.1084/jem.180.4.1243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fischer E., Marano M. A., Barber A. E., Hudson A., Lee K., Rock C. S., Hawes A. S., Thompson R. C., Hayes T. J., Anderson T. D. Comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am J Physiol. 1991 Aug;261(2 Pt 2):R442–R452. doi: 10.1152/ajpregu.1991.261.2.R442. [DOI] [PubMed] [Google Scholar]
  10. Fong Y. M., Marano M. A., Moldawer L. L., Wei H., Calvano S. E., Kenney J. S., Allison A. C., Cerami A., Shires G. T., Lowry S. F. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest. 1990 Jun;85(6):1896–1904. doi: 10.1172/JCI114651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fong Y., Moldawer L. L., Marano M., Wei H., Tatter S. B., Clarick R. H., Santhanam U., Sherris D., May L. T., Sehgal P. B. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol. 1989 Apr 1;142(7):2321–2324. [PubMed] [Google Scholar]
  12. Freudenberg N., Freudenberg M. A., Bandara K., Galanos C. Distribution and localization of endotoxin in the reticulo-endothelial system (RES) and in the main vessels of the rat during shock. Pathol Res Pract. 1985 Mar;179(4-5):517–527. doi: 10.1016/S0344-0338(85)80193-X. [DOI] [PubMed] [Google Scholar]
  13. Giroir B. P., Johnson J. H., Brown T., Allen G. L., Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J Clin Invest. 1992 Sep;90(3):693–698. doi: 10.1172/JCI115939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hack C. E., De Groot E. R., Felt-Bersma R. J., Nuijens J. H., Strack Van Schijndel R. J., Eerenberg-Belmer A. J., Thijs L. G., Aarden L. A. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989 Oct;74(5):1704–1710. [PubMed] [Google Scholar]
  15. Helle M., Boeije L., Aarden L. A. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol. 1988 Oct;18(10):1535–1540. doi: 10.1002/eji.1830181010. [DOI] [PubMed] [Google Scholar]
  16. Ishida T., Lewis R. M., Hartley C. J., Entman M. L., Field J. B. Comparison of hepatic extraction of insulin and glucagon in conscious and anesthetized dogs. Endocrinology. 1983 Mar;112(3):1098–1109. doi: 10.1210/endo-112-3-1098. [DOI] [PubMed] [Google Scholar]
  17. Jones T. H. Interleukin-6 an endocrine cytokine. Clin Endocrinol (Oxf) 1994 Jun;40(6):703–713. doi: 10.1111/j.1365-2265.1994.tb02502.x. [DOI] [PubMed] [Google Scholar]
  18. LeMay D. R., LeMay L. G., Kluger M. J., D'Alecy L. G. Plasma profiles of IL-6 and TNF with fever-inducing doses of lipopolysaccharide in dogs. Am J Physiol. 1990 Jul;259(1 Pt 2):R126–R132. doi: 10.1152/ajpregu.1990.259.1.R126. [DOI] [PubMed] [Google Scholar]
  19. Mathison J. C., Ulevitch R. J. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol. 1979 Nov;123(5):2133–2143. [PubMed] [Google Scholar]
  20. McIntosh J. K., Jablons D. M., Mulé J. J., Nordan R. P., Rudikoff S., Lotze M. T., Rosenberg S. A. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol. 1989 Jul 1;143(1):162–167. [PubMed] [Google Scholar]
  21. Michie H. R., Manogue K. R., Spriggs D. R., Revhaug A., O'Dwyer S., Dinarello C. A., Cerami A., Wolff S. M., Wilmore D. W. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988 Jun 9;318(23):1481–1486. doi: 10.1056/NEJM198806093182301. [DOI] [PubMed] [Google Scholar]
  22. Munck Petersen C., Davidsen O., Moestrup S. K., Sonne O., Nykjaer A., Møller B. K. Cellular targets and receptors for interleukin-6. II. Characterization of IL-6 binding and receptors in peripheral blood cells and macrophages. Eur J Clin Invest. 1990 Aug;20(4):377–384. doi: 10.1111/j.1365-2362.1990.tb01873.x. [DOI] [PubMed] [Google Scholar]
  23. Ohzato H., Monden M., Yoshizaki K., Ogata A., Nishimoto N., Gotoh M., Kishimoto T., Mori T. Systemic production of interleukin-6 following acute inflammation. Biochem Biophys Res Commun. 1993 Dec 30;197(3):1556–1562. doi: 10.1006/bbrc.1993.2655. [DOI] [PubMed] [Google Scholar]
  24. Ruiter D. J., van der Meulen J., Brouwer A., Hummel M. J., Mauw B. J., van der Ploeg J. C., Wisse E. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest. 1981 Jul;45(1):38–45. [PubMed] [Google Scholar]
  25. Shalaby M. R., Waage A., Aarden L., Espevik T. Endotoxin, tumor necrosis factor-alpha and interleukin 1 induce interleukin 6 production in vivo. Clin Immunol Immunopathol. 1989 Dec;53(3):488–498. doi: 10.1016/0090-1229(89)90010-x. [DOI] [PubMed] [Google Scholar]
  26. Shirai M., Nishioka M., Shiga J., Mori W., Fukuda I., Kanegasaki S. Fate of 3H-labeled endotoxin in partially hepatectomised rats. Hepatogastroenterology. 1988 Jun;35(3):107–110. [PubMed] [Google Scholar]
  27. Sonne O., Davidsen O., Møller B. K., Munck Petersen C. Cellular targets and receptors for interleukin-6. I. In vivo and in vitro uptake of IL-6 in liver and hepatocytes. Eur J Clin Invest. 1990 Aug;20(4):366–376. doi: 10.1111/j.1365-2362.1990.tb01872.x. [DOI] [PubMed] [Google Scholar]
  28. Sturk A., Janssen M. E., Muylaert F. R., Joop K., Thomas L. L., ten Cate J. W. Endotoxin testing in blood. Prog Clin Biol Res. 1987;231:371–385. [PubMed] [Google Scholar]
  29. Tovey M. G., Content J., Gresser I., Gugenheim J., Blanchard B., Guymarho J., Poupart P., Gigou M., Shaw A., Fiers W. Genes for IFN-beta-2 (IL-6), tumor necrosis factor, and IL-1 are expressed at high levels in the organs of normal individuals. J Immunol. 1988 Nov 1;141(9):3106–3110. [PubMed] [Google Scholar]
  30. Ulich T. R., Guo K. Z., Irwin B., Remick D. G., Davatelis G. N. Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am J Pathol. 1990 Nov;137(5):1173–1185. [PMC free article] [PubMed] [Google Scholar]
  31. Ulich T. R., Guo K. Z., Remick D., del Castillo J., Yin S. M. Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol. 1991 Apr 1;146(7):2316–2323. [PubMed] [Google Scholar]
  32. van Zaanen H. C., Koopmans R. P., Aarden L. A., Rensink H. J., Stouthard J. M., Warnaar S. O., Lokhorst H. M., van Oers M. H. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest. 1996 Sep 15;98(6):1441–1448. doi: 10.1172/JCI118932. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES